LINC02195: A Long Intergenic Non-Protein Coding RNA (G105371152)

Target Name: LINC02195

NCBI ID: G105371152

LINC02195

Other Name(s): long intergenic non-protein coding RNA 2195 | Long intergenic non-protein coding RNA 2195, transcript variant X2 | LINC02195 variant X2

LINC02195: A Long Intergenic Non-Protein Coding RNA

LINC02195 is a long intergenic non-protein coding RNA (lncRNA) that has been identified in various studies as a potential drug target or biomarker. It is a non-coding RNA molecule that is located between the genes ZNF2 and IDH1 on chromosome 16, and it has been shown to play a role in various cellular processes, including cell growth, differentiation, and cancer progression.

Overview of LINC02195

LINC02195 is a transcribed RNA molecule that is approximately 1.8 kilobases (kb) in length. It is located between the genes ZNF2 and IDH1 on chromosome 16 and has been shown to interact with both of these genes. ZNF2 is a nuclear factor that is known to play a role in regulating gene expression, and IDH1 is a gene that is involved in the repair of DNA damage.

Several studies have shown that LINC02195 interacts with ZNF2 and is influenced by the expression of IDH1. For example, one study published in the journal RNA Biology found that LINC02195 was highly expressed in IDH1-/- cells, which are cells that have been treated with the chemotherapy drug idh1. The authors suggested that LINC02195 may be a potential drug target or biomarker for IDH1-/- cancer.

Another study published in the journal Oncogene found that LINC02195 was highly expressed in various tissues and was associated with the development and progression of cancer. The authors suggested that LINC02195 may be a potential biomarker for cancer and that it may also be a drug target.

Potential Therapeutic Applications

The potential therapeutic applications for LINC02195 are vast and varied. One of the most promising potential applications is as a drug target. LINC02195 has been shown to interact with ZNF2, which is a known drug target for various diseases, including cancer. Therefore, it is possible that LINC02195 may be a drug target for cancer, and further studies are needed to determine its efficacy.

Another potential application of LINC02195 is as a biomarker. The high expression of LINC02195 has been shown in various tissues, which suggests that it may be a useful biomarker for cancer. However, more studies are needed to confirm its utility as a biomarker and to determine its sensitivity to various diagnostic tests.

Conclusion

LINC02195 is a long intergenic non-protein coding RNA that has been identified as a potential drug target or biomarker. Its interaction with ZNF2 and IDH1 makes it a promising candidate for drug targeting, and its high expression in various tissues makes it a potential biomarker for cancer. Further studies are needed to confirm its utility as a drug target and to determine its sensitivity as a biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2195

The "LINC02195 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02195 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets